penumbra

Penumbra (NYSE:PEN) this week posted first-quarter results that beat the revenue consensus on Wall Street but missed earnings estimates. The Alameda, California-based company reported profits of $79,000, or -1¢ per share, on sales of $203.9 million for the three months ended March 31, for a sales growth of 20.5% compared with Q1 … [Read more...] about Penumbra grows sales 20% in Q1

Penumbra (NYSE:PEN) this week posted fourth-quarter results that beat the revenue consensus on Wall Street but missed earnings estimates. The Alameda, California-based company reported losses of -$24.6 million, or -66¢ per share, on sales of $204 million for the three months ended Dec. 31, 2021, for a sales growth of 22.24% compared with Q4 … [Read more...] about Penumbra posts mixed-bag Q4 results, grows sales 22%

Penumbra (NYSE:PEN) announced today that the Cheetah clinical study for its Indigo CAT RX catheter met its primary endpoint. Alameda, California-based Penumbra’s Indigo catheter system demonstrated high rates of blood clot removal, blood flow restoration and myocardial perfusion in conjunction with percutaneous coronary intervention (PCI) in … [Read more...] about Data shows safety and strong performance for Penumbra’s Indigo CAT RX catheter

Penumbra (NYSE:PEN) posted third-quarter results this week that beat the overall consensus on Wall Street. The Alameda, California-based company reported profits of $8.85 million, or 24¢ per share, on sales of $190.1 million for the three months ended Sept. 30, for a sales growth of 25.84% compared with Q3 2020. Adjusted to exclude one-time … [Read more...] about Penumbra beats the Street in Q3, grows sales 25%

Penumbra (NYSE:PEN) posted second-quarter results this week that beat the overall consensus on Wall Street. The Alameda, Calif.-based vascular conditions device company reported profits of $9.2 million, or 25¢ per share, on sales of $184.3 million for the three months ended June 30, for a sales growth of 75.3% compared with Q2 2020. Adjusted … [Read more...] about Penumbra sales grow 75% in Street-beating Q2 results

Penumbra (NYSE:PEN) today said its Red 62 reperfusion catheter has received FDA 510(k) clearance. Alameda, Calif.-based Penumbra designed the catheter to navigate complex distal vessel anatomy and deliver powerful aspiration with its Penumbra Engine to remove blood clots in acute ischemic stroke patients with large vessel occlusions. “In my … [Read more...] about FDA clears Penumbra’s Red 62 reperfusion catheter for removing brain blood clots

Penumbra (NYSE:PEN) yesterday posted first-quarter results that beat the earnings consensus on Wall Street and matched sales estimates. The Alameda, Calif.-based company reported profits of $11.836 million, or 32¢ per share, on sales of $169.2 for the three months ended March 31, for a bottom-line gain of 730.6% sales growth of 23.2% compared … [Read more...] about Penumbra slides on Street-beating Q1 results

A Penumbra recall of certain Jet 7 catheters is Class I – the most serious type of recall, the FDA recently said. The recall, which Penumbra originally announced on Dec. 15, 2020, involved more than 30,000 distributed units of its Jet 7 Reperfusion Catheters with Xtra Flex Technology after the company received 14 reports of death related to the … [Read more...] about FDA: Penumbra recall of some Jet 7 catheters is serious

Penumbra (NYSE:PEN) has issued an urgent voluntary recall of all configurations of its Jet 7 Reperfusion Catheters with Xtra Flex Technology because the catheter may become susceptible to distal tip damage during use. So far, Alameda, Calif.-based Penumbra has received 14 reports of death related to the problem out of the more than 30,000 … [Read more...] about Penumbra recalls some Jet 7 catheters after 14 deaths